Safety, Acceptability and Preliminary Effectiveness of PC-515 for Vaginal Use as a Possible Microbicide

HIV Infections Clinical Trial

Official title:

A Randomized, Placebo-controlled, Double-blind Trial to Assess Expanded Safety, Acceptability and Preliminary Effectiveness of PC-515 (Lambda Carrageenan) for Vaginal Use as a Possible Microbicide

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00213031
• Other study ID #: Population Council #271
• Secondary ID: CDC & Prevention
• Status: Completed
• Phase: Phase 2
• First received: September 13, 2005
• Last updated: August 11, 2017
• Start date: February 2000
• Est. completion date: December 2001

Study information

• Verified date: August 2017
• Source: Population Council
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The primary aims of the study were to assess the safety and acceptability of PC-515 when applied vaginally at least three times weekly for 12 months. Secondary aims were to gather preliminary data on Carraguard's effectiveness in preventing male-to-female transmission of HIV, and other STIs.

The hypothesis was that Carraguard would cause little or no significant irritation, including lesions; and that women would find Carraguard acceptable. The study was not powered to determine effectiveness, but based on safety, acceptability and feasibility parameters, the outcome of the Phase 2 trial would enable a decision whether or not to proceed to a Phase 3 trial.

Description:

Carraguard™ (PC-515), the Population Council's lead candidate microbicide, was tested in a triple-masked, randomized, placebo-controlled trial fielded in one site in Chiang Rai, northern Thailand. The primary aims of the study were to assess Carraguard's safety (toxicity) - including signs of local irritation, such as itching or burning; changes in vaginal flora; and incidence of abnormal external genital, vaginal, and cervical findings - when applied vaginally for 12 months; to evaluate acceptability; to assess feasibility of conducting a large scale microbicide trial in a non-sex worker population; to gauge women's reactions to a non-contraceptive microbicide; and to explore microbicide use dynamics in a Thai population.

Secondary aims were to investigate HIV infections averted (preliminary indications); other sexually transmitted infections averted - including C. trachomatis, N. gonorrhoeae, T. vaginalis, and T. pallidum (preliminary indications); and effect on cervical cytology.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 165
• Est. completion date: December 2001
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• In good health as determined by medical history, physical examination and results of laboratory screening tests

• Aged 18 years or older

• Resident in the area for at least one year and planning to stay for at least 12 months

• HIV-seronegative at baseline

• Willing and able to comply with the study protocol (including being tested for HIV, learning the results, and undergoing clinical evaluations)

• Able to achieve a score of 80% or better on true-false test of key study concepts

• Able to give informed consent

Exclusion Criteria:

• Pregnant or desire to become pregnant at time of study participation

• Delivered or aborted a pregnancy within the six weeks prior to screening

• Male sex partner known at enrollment to be HIV positive

• History of surgery on external genitalia, vagina or cervix in the six weeks prior to screening

• Recent history of non-menstrual vaginal bleeding with intercourse

• Clinically detectable genital abnormality (including presence of warts, or a structural or congenital abnormality)

• Clinical suspicion of a reproductive tract infection (RTI), defined as the presence of a genital ulcer visible to the naked eye, an abnormal vaginal discharge or purulent cervicitis, or untreated positive STD result (Women could be enrolled after treatment of identified RTI. Women with persistent genital epithelial disruption, i.e., ulcer, abrasion or fissure, were not eligible.

• Women with other persistent abnormal signs, such as vaginal or cervical discharge, despite treatment of identified RTI, were eligible)

• Abnormal Pap smear (Class II or above)

• History of sensitivity/allergy to latex

• Concurrent participation in another trial of a vaginal product

• Injection of recreational drugs

Related Conditions & MeSH terms

• Chlamydia Trachomatis
• Gonorrhea
• Herpes Simplex
• HIV Infections
• Neisseria Gonorrhoeae
• Syphilis
• Trichomonas Infections
• Trichomonas Vaginitis
• Vaginitis

Intervention

Drug:
• Carraguard (PC-515)

Locations

Country	Name	City	State
Thailand	Chiang Rai Health Club	Chiang Rai

Sponsors (11)

Lead Sponsor

Collaborator

Population Council

Bill and Melinda Gates Foundation, Centers for Disease Control and Prevention, Chiang Rai District Health Office, Chiang Rai Hospital, Chiang Rai Municipal Health Office, Chiang Rai Public Health Office, Collaboration (TUC), Ministry of Health, Thailand, Nat'l Cntr. for HIV, STD, & TB Prevention Atlanta: Division of STD Prevention,Div. of HIV/AIDS Prevention—Surveillance & Epidemiology, National Center for Infectious Diseases

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety: Genital exam & interview for symptoms after 14 days & monthly thereafter; colposcopy done throughout trial at clinicians' discretion; monthly testing to detect changes in vagina flora.
Primary	Compliance: collection of applicators and interview(monthly)
Primary	Acceptability: interview (quarterly)
Secondary	Preliminary effectiveness: Swabs taken to test for sexually transmitted infections - gonorrhea, chlamydia, trichomoniasis and for genital ulcer disease, if ulceration was detected; blood drawn for syphilis and HIV testing and for HSV-2 Pap smear to det